of curasan Pharma GmbH by Hans-Dieter Rössler.
Product launch of local anesthetics and antibiotics
of CERASORB® in dentistry and maxillofacial surgery
of clinical studies with CERASORB®.
clinical results on CERASORB®.
of the GmbH into an AG and IPO on July 20
launch of stypro®
of CERASORB® in orthopedics and traumatology
of CERASORB® Ortho in the USA.
FDA certification of CERASORB® production facility in Frankfurt, Germany
of CERASORB® M
of the hyaluronic acid injection Curavisc®.
Foundation of curasan, Inc. USA
of the new research, development and production facility in Frankfurt, Germany
for Osbone® Dental in the USA.
CE certification for Osseolive®.
for CERASORB® Paste
for Osseolive® Dental.
CE certification for Ceracell® Foam.
of CERASORB® Foam in the dental sector.
for CERASORB® Ortho Foam in the USA.
Shane Ray new President of curasan, Inc.
of 30 years curasan.
Dr. Alexander Baratta
Dr. Dirk Dembski new CEO.
Dr. Alexander Baratta replaces Dr. Detlef Wilke on the Supervisory Board.
Sale of curavisc to bioventus: curasan strengthens its core business.
Headquarter move to Frankfurt, Germany.
of the subsidiary novaxomx GmbH with the aim of developing osteoinductive growth factors.
Product launch CERASORB® CPC Bone Void Filler.
Product launch BoneFlo®.
Corporate Design and branding.
Product launch CERASORB® Bioactive.
25 years of clinical evidence: CERASORB®.